Nuclear states of 149Pm

Nieschmidt, E. B.; Potnis, V.R.; Ellsworth, L. D.; Mandeville, C. E.

doi:10.1016/0029-5582(65)90642-5

Cited by 12 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…149 Pm has been considered a promising addition to the library of theranostic radionuclides due to its favourable decay characteristics Page 35 of 55 Sadler et al EJNMMI Radiopharmacy and Chemistry (2022) 7:21 and reasonable physical half-life (t 1/2 = 2.21 d) (Hu et al 2002). This radiolanthanoid exhibits appropriate β − -decay characteristics (1.07 MeV (95.9%)) with an accompanying γ-emission (286 keV (2.8%)) which is appropriate for concurrent imaging in theranostic settings as well as for dosimetry and biodistribution evaluation, while also being of low enough energy to avoid dose burden complications in potential clinical applications (Hu et al 2002;Nieschmidt et al 1965;Bunney et al 1960). In addition, the ability for this radionuclide to be produced in no-carrier-added form with high specific activity permits its use in RIT and receptor-targeted radionuclide therapy applications which necessitate high specific activities and radiopurity for successful radiolabelling, with preclinical studies reporting promising results for future applications (Hu et al 2002;Lewis et al 2004;Mohsin et al 2006Mohsin et al , 2011.…”

Section: Promethium: 149 Pmmentioning

confidence: 99%

“…Radiolabelling and preclinical investigation into the in vitro stability, in vivo stability and biodistribution of aminocarboxylate and octreotide complexes of no-carrier-added 149 Pm in comparison with the analogous 166 Ho and 177 Lu complexes has also been conducted (Li et al 2003). Production of 149 Pm in no-carrier-added form is readily achieved by means of neutron bombardment of enriched 148 Nd targets via the 148 Nd(n,γ) 149 Nd nuclear reaction (σ th = 2.5 barn) with subsequent β − -decay of 149 Nd (t 1/2 = 1.73 h) to 149 Pm, potentially allowing for theoretical specific activities of 15 GBq/mg (Uusijärvi et al 2006;Nieschmidt et al 1965;Bunney et al 1960;Abrarov and Aminova 1975). The use of highly enriched 148 Nd targets ensures the avoidance of coproduction of the reasonably longlived 147 Nd (t 1/2 = 11 d) impurity due to the comparable thermal neutron capture crosssection of the 146 Nd(n,γ) 147 Nd nuclear reaction (σ th = 1.4 barn).…”

Section: Promethium: 149 Pmmentioning

confidence: 99%

See 1 more Smart Citation

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i.e. a “one-size-fits-all” approach. This review will focus on recent progress and innovations in the area of Rare Earth radionuclides for theranostic applications by providing a detailed snapshot of their current state of production by means of nuclear reactions, subsequent promising theranostic capabilities in the clinic, as well as a discussion of factors that have impacted upon their progress through the theranostic drug development pipeline. Main body In light of this interest, a great deal of research has also been focussed towards certain under-utilised Rare Earth radionuclides with diverse and favourable decay characteristics which span the broad spectrum of most cancer imaging and therapeutic applications, with potential nuclides suitable for α-therapy (149Tb), β−-therapy (47Sc, 161Tb, 166Ho, 153Sm, 169Er, 149Pm, 143Pr, 170Tm), Auger electron (AE) therapy (161Tb, 135La, 165Er), positron emission tomography (43Sc, 44Sc, 149Tb, 152Tb, 132La, 133La), and single photon emission computed tomography (47Sc, 155Tb, 152Tb, 161Tb, 166Ho, 153Sm, 149Pm, 170Tm). For a number of the aforementioned radionuclides, their progression from ‘bench to bedside’ has been hamstrung by lack of availability due to production and purification methods requiring further optimisation. Conclusions In order to exploit the potential of these radionuclides, reliable and economical production and purification methods that provide the desired radionuclides in high yield and purity are required. With more reactors around the world being decommissioned in future, solutions to radionuclide production issues will likely be found in a greater focus on linear accelerator and cyclotron infrastructure and production methods, as well as mass separation methods. Recent progress towards the optimisation of these and other radionuclide production and purification methods has increased the feasibility of utilising Rare Earth radiometals in both preclinical and clinical settings, thereby placing them at the forefront of radiometals research for cancer theranostics.

show abstract

Section: Promethium: 149 Pmmentioning

confidence: 99%

Section: Promethium: 149 Pmmentioning

confidence: 99%

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

“…149 Pm (t 1/2 = 2.21 d) is a high specific activity radiolanthanide that is suitable for targeting of limited numbers of specific receptors found on many tumor cells [69][70][71][72][73]. 149 Pm emits b À particles of moderate energy (1.071 MeV) and c photons with an energy of 285 keV (2.8%), making in vivo imaging possible [74]. Stable isotopes of promethium do not exist, precluding the direct neutron activation of targets.…”

Section: Promethium-149mentioning

confidence: 99%

Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications

Voorde

Hecke

Cardinaels

et al. 2019

Coordination Chemistry Reviews

View full text Add to dashboard Cite

“…A series of delayedcoincidence measurements [16,17] established nanosecond range lifetimes for several states. Studies first made by Nieschmidt, et al [18], Helmer and Mclssac [14] and Gopinathan and Singru [19] combined Ge(Li) detector spectrometry, internal conversion electron spectrograph and coincidence arrangements to produce a list of about 70 gamma-ray energies and 10 well established levels. Angular correlations [20,21] enabled the establishment of spin assignments for some of the levels.…”

Section: Introductionmentioning

confidence: 99%

Radioactive decay of 1.7-h149Nd to levels of transitional149Pm

Schneider

Glascock²,

Walters³

et al. 1979

Z Physik A

View full text Add to dashboard Cite

Sources of 149Nd were produced by thermal-neutron irradiation of enriched 148Nd. High resolution Ge(Li) spectrometers were used to collect gamma-ray singles and coincidence spectra in the study of the decay of 1.7-h 149Nd. A total of 214 gamma rays have been assigned to the decay of a49Nd, and 201 of these transitions have been placed in a level scheme of 149pm involving 42 excited states. Absolute values for the beta-group intensities were determined for transitions to the 149pm levels, and spin and parity assignments were made for many of the observed states. The experimentally determined level structure of 149pm was compared with corresponding levels in other odd-mass Pm and Eu nuclides. Interpretations were made in terms of the core-coupling model.Radioactive Decay: 148Nd(n, 7) 149Nd; measured E~, I~., ~-7 coinc. 149pm deduced levels, J, ~. Compton-suppression. Ge(Li) detector. Enriched targets.

show abstract

Nuclear states of 149Pm

Cited by 12 publications

References 4 publications

Cutting edge rare earth radiometals: prospects for cancer theranostics

Cutting edge rare earth radiometals: prospects for cancer theranostics

Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications

Radioactive decay of 1.7-h149Nd to levels of transitional149Pm

Contact Info

Product

Resources

About